March 17, 2023 MonoVer® (ferric derisomaltose) is launched in Japan for the treatment of iron deficiency anaemia


March 17th, 2023

Holbaek, Denmark: Pharmacosmos is pleased to announce that MonoVer® (ferric derisomaltose) has been granted national reimbursement in Japan and is subsequently being launched in the world’s 3rd largest pharma market. MonoVer® is an intravenous (IV) iron indicated in Japan for the treatment of iron deficiency anaemia (IDA) when oral iron preparations are ineffective or cannot be used; or where there is a clinical need to deliver iron rapidly. 

MonoVer® is being introduced to the Japanese market by Pharmacosmos’ strategic partner Nippon Shinyaku Co., Ltd (Headquarters, Kyoto, Japan; President, Toru Nakai) – a leading pharmaceutical company with more than 2000 employees and with a track record of bringing new innovative products to the Japanese market since its establishment more than a century ago. 

The Japanese iron deficiency anaemia market is a fast-growing IV iron market driven by a high prevalence of patients with IDA and an increase in the treatment with IV iron. 

‘The launch in Japan marks a milestone for Pharmacosmos, since we are now represented with ferric derisomaltose in the 3 largest global pharma markets’ said Tobias S. Christensen, President and CEO of Pharmacosmos A/S. ‘Our product fit with the needs of Japanese patients and hospitals, and the strength of our partner Nippon Shinyaku makes us see this opportunity as very promising for Pharmacosmos’.

Contact information
Christian Lundquist Madsen, Head of Global Marketing
+45 5948 5959,

About Pharmacosmos Group

Pharmacosmos Group, headquartered in Holbaek, Denmark, and founded in 1965, is a highly specialised company focused on carbohydrate chemistry and a global leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anaemia. With companies in the UK, Nordics, Germany, the USA, and China, as well as through partners, Pharmacosmos markets its products around the world. With a strong and ongoing commitment to R&D, Pharmacosmos is able to leverage a unique carbohydrate production platform along with deep expertise in the synthesis of iron-carbohydrate complexes. The Pharmacosmos Group has approximately 500 employees.


Based on Nippon Shinyaku’s business philosophy, “Helping people lead healthier, happier lives,” we aim to be an organization trusted by the community through creating unique medicines that will bring hope to patients and families suffering from illness. Please visit the website ( for products or detailed information.


Please identify if you are a: